- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT06216301
LUNAR-2: TTFields med Pembrolizumab + platinabaserad kemoterapi för metastatisk NSCLC (LUNAR-2)
LUNAR-2: Pivotal, randomiserad, öppen studie av tumörbehandlingsfält (TTFields, 150 kHz) samtidigt med Pembrolizumab och platinabaserad kemoterapi för behandling av metastaserad icke-småcellig lungcancer
This study, known as LUNAR-2, aims to investigate the effectiveness and safety of using TTFields, delivered by the NovoTTF-200T device, concomitantly administered with pembrolizumab and platinum-based chemotherapy for patients with advanced non-small cell lung cancer that has spread to other parts of the body. The primary goals of the study are to assess overall survival and progression-free survival. Secondary objectives include analyzing outcomes based on the specific histology (subtype) of the lung cancer.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
LUNAR-2 is a pivotal, randomized, open-label study that aims to evaluate the effectiveness and safety of Tumor Treating Fields (TTFields) concomitantly administered with pembrolizumab and platinum-based chemotherapy for the treatment of metastatic non-small cell lung cancer (NSCLC).
The primary objectives of the study are to assess overall survival (OS) and progression-free survival (PFS) in subjects treated with TTFields, pembrolizumab, and platinum-based chemotherapy compared to those treated with pembrolizumab and platinum-based chemotherapy alone. PFS will be evaluated by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.
The secondary endpoints of this study will evaluate PFS and OS, stratified by the specific histological subtype of NSCLC and PD-L1 Tumor Proportion Score (TPS).
The population will consist of subjects with an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1 and will be stratified as follow:
- Histology - Squamous vs. non-squamous
- PD-L1 expression level - TPS <1% vs. 1% ≤TPS <50% vs. TPS ≥50%
- Prior treatment with immunotherapy - yes vs. no
The study will be conducted globally at approximately 130 participating sites. The study device, NovoTTF-200T, is a portable, battery-operated system that delivers TTFields at a frequency of 150kHz. It utilizes insulated transducer arrays to deliver electric forces intended to disrupt cancer cell division.
Studietyp
Inskrivning (Beräknad)
Fas
- Fas 3
Kontakter och platser
Studieorter
-
-
-
Brussels, Belgien, 1200
- Aktiv, inte rekryterande
- Cliniques universitaires Saint-Luc
-
Ghent, Belgien, 9000
- Aktiv, inte rekryterande
- AZ Maria Middelares - Campus Maria Middelares
-
-
-
-
-
Créteil, Frankrike, 94010
- Rekrytering
- Centre Hospitalier Intercommunal de Creteil
-
Kontakt:
- Christos Chouaid
- Telefonnummer: +33 1 57 02 20 70
- E-post: christos.chouaid@chicreteil.fr
-
Limoges, Frankrike, 87000
- Avslutad
- CHU Limoges
-
Marseille, Frankrike, 13003
- Avslutad
- Hopital Europeen
-
Nantes, Frankrike, 44277
- Rekrytering
- Hopital Prive du Confluent
-
Huvudutredare:
- Cyriac Blonz
-
Kontakt:
- Cyriac Blonz
- Telefonnummer: +33 2 28 27 20 88
- E-post: BLONZ.CYRIAC@groupeconfluent.fr
-
Paris, Frankrike, 75005
- Rekrytering
- Institut Curie
-
Kontakt:
- Nicolas Girard
- Telefonnummer: 33144324677
- E-post: nicolas.girard2@curie.fr
-
Pessac, Frankrike, 33604
- Rekrytering
- CHU de Bordeaux
-
Kontakt:
- Claire Bardel
- Telefonnummer: +33 5 57 65 63 38
- E-post: claire.bardel@chu-bordeaux.fr
-
Pierre-Bénite, Frankrike, 69495
- Avslutad
- Centre Hospitalier Lyon Sud
-
Strasbourg, Frankrike, 67091
- Rekrytering
- Nouvel Hopital Civil (NHC)
-
Kontakt:
- Celine Mascaux
- Telefonnummer: 33-3-69 55 06 44
- E-post: celine.mascaux@chru-strasbourg.fr
-
-
-
-
Alabama
-
Birmingham, Alabama, Förenta staterna, 35209
- Avslutad
- Central Alabama Research
-
-
Arizona
-
Goodyear, Arizona, Förenta staterna, 85338
- Aktiv, inte rekryterande
- Western Regional Medical Center, LLC
-
-
California
-
Fullerton, California, Förenta staterna, 92835
- Rekrytering
- St. Jude Herritage Medical Group
-
Kontakt:
- Larissa Ulloa
- Telefonnummer: 800-627-8106
- E-post: larissa.lacson@providence.org
-
Newport Beach, California, Förenta staterna, 92663
- Rekrytering
- Hoag Family Cancer Institute - Hoag Memorial Hospital
-
Kontakt:
- Patrice Jones
- Telefonnummer: 949-764-5501
- E-post: Patrice.Jones@hoag.org
-
Sacramento, California, Förenta staterna, 95816
- Aktiv, inte rekryterande
- Sutter Institute for Medical Research
-
-
Florida
-
Jacksonville, Florida, Förenta staterna, 32207
- Rekrytering
- Baptist MD Anderson Cancer Center, Baptist Health
-
Kontakt:
- Vanessa Tolsa
- Telefonnummer: 305-915-6496
- E-post: vanessa.tolsa@bmcjax.com
-
Huvudutredare:
- John Vu
-
Ocala, Florida, Förenta staterna, 34474
- Avslutad
- Florida Cancer Affiliates - Ocala Oncology
-
Tampa, Florida, Förenta staterna, 33612
- Rekrytering
- Moffitt Cancer Center
-
Kontakt:
- Maya Douglas
- Telefonnummer: 813-745-0969
- E-post: maya.douglas@moffitt.org
-
-
Illinois
-
Barrington, Illinois, Förenta staterna, 60010
- Aktiv, inte rekryterande
- Northwest Oncology & Hematology
-
Elmhurst, Illinois, Förenta staterna, 60126
- Aktiv, inte rekryterande
- Elmhurst Hospital Nancy Knowles Cancer Center
-
Naperville, Illinois, Förenta staterna, 60540-6766
- Avslutad
- Edward Cancer Center
-
Zion, Illinois, Förenta staterna, 60099
- Rekrytering
- Cancer Treatment Centers of America (CTCA)
-
Kontakt:
- Sylvia Schneiderman
- Telefonnummer: 1-847-746-6983
- E-post: sylvia.schneiderman@coh.org
-
-
Indiana
-
Fort Wayne, Indiana, Förenta staterna, 46845
- Rekrytering
- Parkview Packnett Family Cancer Institute
-
Huvudutredare:
- Brian Chang
-
Kontakt:
- Brian Chang, Dr.
- Telefonnummer: 1-833-724-8326
- E-post: brian2.chang@parkview.com
-
Indianapolis, Indiana, Förenta staterna, 46237
- Avslutad
- Franciscan Health Indianapolis
-
-
Kansas
-
Westwood, Kansas, Förenta staterna, 66205
- Aktiv, inte rekryterande
- University of Kansas Cancer Center
-
-
Maryland
-
Annapolis, Maryland, Förenta staterna, 21401
- Avslutad
- Luminis Health Radiation Oncology - Anne Arundel Health System
-
-
Missouri
-
Kansas City, Missouri, Förenta staterna, 64154
- Aktiv, inte rekryterande
- University of Kansas Cancer Center - North
-
Lee's Summit, Missouri, Förenta staterna, 64064
- Aktiv, inte rekryterande
- University of Kansas Cancer Center - Lee's Summit
-
Overland, Missouri, Förenta staterna, 66210
- Aktiv, inte rekryterande
- University of Kansas Cancer Center - Overland Park
-
-
New York
-
New Hyde Park, New York, Förenta staterna, 11042
- Avslutad
- New York Cancer & Blood Specialists (NYCBS)
-
New York, New York, Förenta staterna, 10028
- Avslutad
- New York Cancer & Blood Specialists (NYCBS)
-
Rochester, New York, Förenta staterna, 14642
- Avslutad
- University of Rochester Medical Center
-
Shirley, New York, Förenta staterna, 11967
- Avslutad
- New York Cancer & Blood Specialists (NYCBS)
-
The Bronx, New York, Förenta staterna, 10469
- Avslutad
- New York Cancer & Blood Specialists (NYCBS)
-
-
North Carolina
-
Cary, North Carolina, Förenta staterna, 27518
- Rekrytering
- WakeMed Health & Hospitals
-
Kontakt:
- Taylor Childress
- Telefonnummer: 14842 919-350-1700
- E-post: tchildress@wakemed.org
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Förenta staterna, 19104
- Rekrytering
- Abramson Cancer Center
-
Kontakt:
- Ryan Roddy
- Telefonnummer: 267-408-3199
- E-post: ryan.roddy@pennmedicine.upenn.edu
-
Pittsburgh, Pennsylvania, Förenta staterna, 15212
- Rekrytering
- AHN Cancer Center
-
Kontakt:
- Ariel Lopez-Chavez
- Telefonnummer: 412-518-5025
- E-post: clinicaltrials@ahn.org
-
-
Texas
-
Dallas, Texas, Förenta staterna, 75235
- Rekrytering
- UT Southwestern Medical Center
-
Kontakt:
- Ebele Mbanugo
- Telefonnummer: 214-645-0326
- E-post: ebele.mbanugo@utsouthwestern.edu
-
Dallas, Texas, Förenta staterna, 75235
- Rekrytering
- Old Parkland Hospital Hematology Oncology Clinic
-
Kontakt:
- Ebele Mbanugo
- Telefonnummer: 214-645-0326
- E-post: ebele.mbanugo@utsouthwestern.edu
-
Edinburg, Texas, Förenta staterna, 78539
- Rekrytering
- DHR Health Oncology Institute
-
Kontakt:
- Edgar Lopez
- Telefonnummer: 956-362-2394
- E-post: ed.lopez@dhr-rgv.com
-
Houston, Texas, Förenta staterna, 77030
- Rekrytering
- Houston Methodist Cancer Center
-
Huvudutredare:
- Jun Zhang
-
Kontakt:
- Nicole Barrios
- Telefonnummer: 713-441-5607
- E-post: nkbarrios@houstonmethodist.org
-
Richardson, Texas, Förenta staterna, 75082
- Rekrytering
- Methodist Richardson Cancer Center
-
Kontakt:
- Crystee Cooper
- Telefonnummer: 214-947-1280
- E-post: ClinicalResearch@mhd.com
-
San Antonio, Texas, Förenta staterna, 78229
- Avslutad
- Jason Bates at University of Texas Health Science Center
-
-
Washington
-
Auburn, Washington, Förenta staterna, 98001
- Avslutad
- MultiCare Regional Cancer Center
-
Gig Harbor, Washington, Förenta staterna, 98335
- Avslutad
- MultiCare Regional Cancer Center
-
Puyallup, Washington, Förenta staterna, 98372
- Avslutad
- MultiCare Regional Cancer Center
-
Spokane, Washington, Förenta staterna, 99218
- Avslutad
- MultiCare Deaconess Cancer and Blood Specialty Center - Downtown
-
Tacoma, Washington, Förenta staterna, 98405
- Avslutad
- MultiCare Institute for Research & Innovation
-
-
-
-
-
Afula, Israel, 1834111
- Aktiv, inte rekryterande
- Emek Medical Center
-
Haifa, Israel, 34561
- Aktiv, inte rekryterande
- Bnai zion MC
-
-
-
-
-
Alessandria, Italien, 15121
- Avslutad
- A.O. SS. Antonio e Biagio e Cesare Arrigo di Alessandria
-
Bergamo, Italien, 24125
- Aktiv, inte rekryterande
- Humanitas Gavazzeni
-
Ferrara, Italien, 44124
- Aktiv, inte rekryterande
- Azienda Ospedaliero-Universitaria di Ferrara - Arcispedale Sant'Anna
-
Meldola, Italien, 47014
- Rekrytering
- IRCCS - Istituto Romagnolo per lo Studio Dei Tumori, Dino Amadori
-
Kontakt:
- Angelo Delmonte
- Telefonnummer: +39 0543 739100
- E-post: angelo.delmonte@irst.emr.it
-
Pesaro, Italien, 61122
- Aktiv, inte rekryterande
- Azienda Sanitaria Territoriale Pesaro Urbino
-
Roma, Italien, 00128
- Avslutad
- Universita Campus Bio-Medico di Roma (UCBM) - Policlinico Universitario
-
Rome, Italien, 00186
- Avslutad
- Ospedale Isola Tiberina Gemelli
-
Siena, Italien, 53100
- Avslutad
- Azienda Ospedaliera Universitaria Senese Policlinico Le Scotte
-
-
-
-
Osaka
-
Osaka, Osaka, Japan, 541-8567
- Rekrytering
- Osaka International Cancer Institute
-
Kontakt:
- Kei Kunimasa
- Telefonnummer: 06-6945-1181
- E-post: kei.kunimasa@oici.jp
-
Huvudutredare:
- Kei Kunimasa
-
Sakai, Osaka, Japan, 590-0197
- Rekrytering
- Kindai University Hospital
-
Huvudutredare:
- Hidetoshi Hayashi
-
Kontakt:
- Hidetoshi Hayashi
- Telefonnummer: 81-72-288-7222
- E-post: hidet31@med.kindai.ac.jp
-
-
Saitama
-
Hidaka, Saitama, Japan, 350-1298
- Rekrytering
- Saitama Medical University International Medical Center
-
Kontakt:
- Saitama Medical University International Medical Center
- Telefonnummer: 042-984-4183
- E-post: chikenme@saitama-med.ac.jp
-
-
Tokyo
-
Bunkyo, Tokyo, Japan, 113-8431
- Rekrytering
- Juntendo University
-
Huvudutredare:
- Takehito Shukuya
-
Kontakt:
- Takehito Shukuya
- Telefonnummer: 81-3-3814-5672
- E-post: tshukuya@juntendo.ac.jp
-
Chuo-ku, Tokyo, Japan, 104-0045
- Rekrytering
- National Cancer Center Hospital
-
Huvudutredare:
- Hidehito Horinouchi
-
Kontakt:
- Hidehito Horinouchi
- Telefonnummer: 81-3542-2511
- E-post: hhorinou@ncc.go.jp
-
-
-
-
Alberta
-
Edmonton, Alberta, Kanada, T6G 1Z2
- Rekrytering
- Cross Cancer Institute/University of Alberta
-
Kontakt:
- Haidar El Darsa
- Telefonnummer: (780) 432-8340
- E-post: Haidar.ElDarsa@CancerCareAlberta.ca
-
Huvudutredare:
- Haidar El Darsa
-
-
Ontario
-
Ottawa, Ontario, Kanada, K1H 8L6
- Rekrytering
- The Ottawa Hospital Cancer Centre General Campus
-
Huvudutredare:
- Garth Nicholas
-
Kontakt:
- Garth Nicholas
- Telefonnummer: 70175 613-737-7700
- E-post: gnicholas@toh.ca
-
Toronto, Ontario, Kanada, M4N 3M5
- Rekrytering
- Sunnybrook Health Sciences Center
-
Kontakt:
- Vaishali Krishnanandan
- Telefonnummer: 67955 416-480-5000
- E-post: vaishali.krishnanandan@sunnybrook.ca
-
Huvudutredare:
- Susanna Cheng
-
-
Quebec
-
Montreal, Quebec, Kanada, H2L 4M1
- Rekrytering
- CHUM
-
Huvudutredare:
- David Roberge
-
Kontakt:
- Mom Phat
- Telefonnummer: 514-890-8254
- E-post: mom.phat.chum@ssss.gouv.qc.ca
-
-
-
-
-
Arnhem, Nederländerna, 6815AD
- Avslutad
- Rijnstate Ziekenhuis
-
Friesland, Nederländerna, 8934 AD
- Avslutad
- Medisch Centrum Leeuwarden (MCL) - Oncologisch Centrum Leeuwarden (OCL)
-
Harderwijk, Nederländerna, 3844 DG
- Aktiv, inte rekryterande
- St. Jansdal ziekenhuis
-
Utrecht, Nederländerna, 3543 AZ
- Avslutad
- St Antonius Ziekenhuis
-
-
-
-
-
Poznan, Polen, 60-693
- Avslutad
- Uniwersytecki Szpital Kliniczny
-
-
-
-
-
Baden, Schweiz, 5404
- Avslutad
- Cantonal Hospital Baden
-
Fribourg, Schweiz, 1752
- Aktiv, inte rekryterande
- HFR Freiburg-Kantonsspital
-
-
-
-
-
Singapore, Singapore, 168583
- Aktiv, inte rekryterande
- NCCS Singapore
-
Singapore, Singapore, 329563
- Avslutad
- Curie Oncology
-
Singapore, Singapore, 574623
- Aktiv, inte rekryterande
- Icon Cancer Centre Singapore (Singapore Oncology Consultants)
-
-
-
-
-
Barcelona, Spanien, 8916
- Rekrytering
- Institut Catala d'Oncologia
-
Kontakt:
- Enric Carcereny Costa
- Telefonnummer: +34 677 254 583
- E-post: ecarcereny@iconcologia.net
-
Lleida, Spanien, 25198
- Aktiv, inte rekryterande
- Hospital Universitario Arnau de Vilanova
-
Madrid, Spanien, 28027
- Aktiv, inte rekryterande
- Clinica Universidad de Navarra (Madrid)
-
Madrid, Spanien, 28034
- Avslutad
- Hospital Ruber Internacional
-
Málaga, Spanien, 29010
- Rekrytering
- Hospital Regional Universitario de Malaga
-
Kontakt:
- Airam Padilla Alvarez
- Telefonnummer: +34 951 308 130
- E-post: airampadillaalvarez@gmail.com
-
Pamplona, Spanien, 31008
- Rekrytering
- Clinica Universidad de Navarra
-
Kontakt:
- Miguel Fernandez de Sanmamed Gutierrez
- Telefonnummer: +34 948255400
- E-post: msanmamed@unav.es
-
-
Alicante
-
Elche, Alicante, Spanien, 3293
- Avslutad
- Hospital Universitario del Vinalopo
-
-
Andalusia
-
Seville, Andalusia, Spanien, 41013
- Aktiv, inte rekryterande
- Hospital Universitario Virgen del Rocio
-
-
Catalonia
-
Barcelona, Catalonia, Spanien, 8017
- Rekrytering
- Clinica Mi Tres Torres Barcelona - Giromed Institute
-
Kontakt:
- Carlos Cabrera Galvez
- Telefonnummer: +34 932 287 445
- E-post: ccabrera@uomi.es
-
-
Madrid
-
Torrejón de Ardoz, Madrid, Spanien, 28850
- Rekrytering
- Hospital Universitario de Torrejon
-
Kontakt:
- Luis Cabezon Gutierrez
- Telefonnummer: +34 916262626
- E-post: lcabezon@torrejonsalud.com
-
-
-
-
Greater London
-
London, Greater London, Storbritannien
- Rekrytering
- Charing Cross Hospital
-
Kontakt:
- Denebeth Calla
- Telefonnummer: 020-331-10291
- E-post: Denebeth.calla@nhs.net
-
Huvudutredare:
- Waleed Mohammed
-
-
Leicestershire
-
Leicester, Leicestershire, Storbritannien, LE1 5WW
- Rekrytering
- University Hospitals of Leicester NHS Trust
-
Kontakt:
- Clare Belcher
- Telefonnummer: 01162586935
- E-post: clare.belcher2@nhs.net
-
Huvudutredare:
- Sean Dulloo
-
-
London
-
London, London, Storbritannien, SW3 6JJ
- Rekrytering
- The Royal Marsden NHS Foundation Trust
-
Kontakt:
- Michael Davidson
- Telefonnummer: +44 20 7352 8171
- E-post: lung.trials@rmh.nhs.uk
-
-
Merseyside
-
Liverpool, Merseyside, Storbritannien, L7 8YA
- Rekrytering
- Clatterbridge Cancer Centre - Liverpool
-
Huvudutredare:
- Carles Escriu
-
Kontakt:
- William McCaig
- Telefonnummer: 07795 129946
- E-post: william.mccaig1@nhs.net
-
-
Sutton
-
Sutton, Sutton, Storbritannien, SM2 5PT
- Rekrytering
- The Royal Marsden NHS Foundation Trust - Sutton
-
Kontakt:
- Michael Davidson
- Telefonnummer: +44 20 7352 8171
- E-post: lung.trials@rmh.nhs.uk
-
-
-
-
-
Olomouc, Tjeckien, 779 00
- Avslutad
- Fakultni nemocnice Olomouc FNOL
-
Ostrava, Tjeckien, 70300
- Aktiv, inte rekryterande
- Nemocnice Agel Ostrava-Vitkovice / Agel Ostrava-Vitkovice Hospital
-
Prague, Tjeckien, 12808
- Aktiv, inte rekryterande
- General University Hospital in Prague
-
-
-
-
-
Berlin, Tyskland, 13125
- Aktiv, inte rekryterande
- Evangelische Lungenklinik Berlin
-
Giessen, Tyskland, 35392
- Rekrytering
- University Hospital Giessen, ZIM IV
-
Kontakt:
- Anika Holzapfel
- Telefonnummer: +49 641 985 59263
- E-post: Anika.Holzapfel@uniklinikum-giessen.de
-
Halle, Tyskland, 06120
- Rekrytering
- Krankenhaus Martha-Maria Halle-Dolau
-
Huvudutredare:
- Wolfgang Schuette
-
Kontakt:
- Franziska Gebauer
- Telefonnummer: +49 345 559 1434
- E-post: franziska.gebauer@martha-maria.de
-
Heidelberg, Tyskland, 69126
- Aktiv, inte rekryterande
- Thoraxklinik Heidelberg
-
Löwenstein, Tyskland, 74245
- Avslutad
- Klinik Loewenstein gGmbH
-
Oldenburg, Tyskland, 26121
- Avslutad
- Pius-Hospital Oldenburg
-
-
-
-
-
Farkasgyepű, Ungern, 8582
- Aktiv, inte rekryterande
- Farkasgyepui Tudogyogyintezet
-
Kecskemét, Ungern, 6000
- Aktiv, inte rekryterande
- Bacs-Kiskun Varmegyei Oktatokorhaz
-
Szekszárd, Ungern, 7100
- Rekrytering
- Tolna Varmegyei Balassa Janos Korhaz
-
Kontakt:
- Yousuf Al-Farhat
- Telefonnummer: +36 30 644 1744
- E-post: yalfarhat@gmail.com
-
-
-
-
-
Innsbruck, Österrike, 6020
- Aktiv, inte rekryterande
- Universitaetsklinik fuer Innere Medizin V Innsbruck
-
Salzburg, Österrike, 5020
- Aktiv, inte rekryterande
- University Hospital Salzburg
-
Vienna, Österrike, 1210
- Aktiv, inte rekryterande
- Karl Landsteiner Institut fur Lungenforschung und pneumologische Onkologie c/o Klinik Floridsdorf
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria
-
≥22 years of age in the USA
≥18 years of age outside of the USA.
-
Histologically or cytologically diagnosis of stage 4 (according to Version 8 of the American Joint Committee on Cancer [AJCC] criteria) non-squamous or squamous NSCLC.
-
Evaluable (measurable or non-measurable) disease in the thorax per RECIST v1.1.
-
Have not received prior systemic treatment for their metastatic NSCLC. Subjects who received adjuvant, neoadjuvant chemotherapy or chemoradiotherapy with curative intent for non-metastatic disease are eligible if the therapy was completed at least 12 months prior to the development of metastatic disease.
-
ECOG Performance Status (PS) of 0-1.
-
Adequate hematologic and end-organ function
o For subjects not receiving therapeutic anticoagulation: INR or aPTT ≤ 1.5 x ULN (unless participant is receiving anticoagulant therapy as long as INR or aPTT is within therapeutic range of intended use of anticoagulants).
-
A female participant is eligible to participate if she is not pregnant, not breastfeeding
-
If male subject with a female partner(s) of child-bearing potential, must agree to use an effective contraception
-
All subjects must sign written informed consent.
Exclusion Criteria:
All individuals meeting any of the following exclusion criteria will be excluded from study participation:
-
Mixed small cell and NSCLC histology.
-
EGFR sensitizing mutation and/or ALK translocation, and/or ROS1 and/or RET targetable gene rearrangement, and/or METex14 skipping mutation, and/or NTRK1/2 gene fusion and/or BRAF V600 mutations directed therapy is indicated or planned for other targeted therapy, where such testing and therapy is locally approved and available.
-
Has received systemic therapy for metastatic disease.
-
Had major surgery <3 weeks prior to randomization
-
Received radiation therapy to the lung that is > 30 Gy within 6 months of randomization.
-
Has received prior radiotherapy within 2 weeks of randomization. Subjects must have recovered from all radiation-related toxicities, not require corticosteroids, and not have had radiation pneumonitis. A 1-week washout is permitted for palliative radiation (≤2 weeks of radiotherapy) to non-CNS disease.
-
Is expected to require any other form of antineoplastic therapy while on study.
-
Has a known additional malignancy that is progressing or has required active treatment within the past 3 years.
- Note: Subjects with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ (e.g., breast carcinoma, cervical cancer in situ) that have undergone potentially curative therapy are not excluded
-
Has symptomatic Central Nervous System (CNS) metastases and/or carcinomatous meningitis. Subjects with asymptomatic CNS metastases or with previously treated brain metastases may participate provided they were treated before randomization (if applicable) and are neurologically stable and without requirement of steroid treatment for at least 7 days prior to randomization.
-
Has active autoimmune disease that has required systemic treatment in past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs).
-
Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior randomization. Subjects with asthma that require intermittent use of bronchodilators, inhaled steroids, or local steroid injections would not be excluded from the study.
-
Had prior treatment with any other anti-PD-1, or PD-L1 or PD-L2 agent or an antibody or a small molecule targeting other immuno-regulatory receptors or mechanisms in the 12 months prior to randomization.
-
Participation in another clinical study with an investigational agent or device during the 4 weeks prior to randomization.
-
Concurrent treatment with other experimental treatments for NSCLC while in the study.
-
Has a known sensitivity to any component of the planned systemic therapies (pembrolizumab, cisplatin/carboplatin, pemetrexed/paclitaxel/nab-paclitaxel) .
-
Pregnant or breastfeeding
-
Admitted to an institution by administrative or court order.
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Arm 1: NovoTTF-200T, Pembrolizumab, and Platinum-based Chemotherapy
Subjects in this arm receive three treatments - TTFields using the NovoTTF-200T device, pembrolizumab, and platinum-based chemotherapy. |
The NovoTTF-200T is a portable, battery operated system intended for continuous home use, which delivers TTFields at a frequency of 150kHz to the subject by means of insulated transducer arrays. TTFields physically disrupt the rapid cell division exhibited by cancer cells. The physical disruption induced by TTFields can lead to to downstream immunogenic cell death. Pembrolizumab is an immune checkpoint inhibitor that helps the immune system recognize and attack cancer cells. Platinum-based chemotherapy is a standard chemotherapy regimen commonly used in the treatment of non-small cell lung cancer |
|
Aktiv komparator: Arm 2: Pembrolizumab and Platinum-based Chemotherapy
Subjects in this arm receive two treatments - pembrolizumab and platinum-based chemotherapy. |
Pembrolizumab is an immune checkpoint inhibitor that helps the immune system recognize and attack cancer cells. Platinum-based chemotherapy is a standard chemotherapy regimen commonly used in the treatment of non-small cell lung cancer |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Overall Survival (OS)
Tidsram: up to 6 years
|
To compare OS in subjects treated with TTFields concomitant with pembrolizumab and platinum-based chemotherapy compared to OS of those treated with pembrolizumab and platinum-based chemotherapy alone (superiority analysis). |
up to 6 years
|
|
Progression Free Survival (PFS)
Tidsram: up to 6 years
|
To compare PFS per RECIST v1.1 as assessed by BICR, in subjects treated with TTFields concomitant with pembrolizumab and platinum-based chemotherapy compared to PFS of those treated with pembrolizumab and platinum-based chemotherapy alone (superiority analysis) |
up to 6 years
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Progression Free Survival (PFS)
Tidsram: up to 6 years
|
Progression Free Survival (PFS) per RECIST v1.1 as assessed by BICR, in subjects treated with TTFields concomitant with pembrolizumab and platinum-based chemotherapy and of those treated with pembrolizumab and platinum-based chemotherapy alone according to histology. |
up to 6 years
|
|
Overall Survival (OS)
Tidsram: up to 6 years
|
Overall Survival (OS) in subjects treated with TTFields concomitant with pembrolizumab and platinum-based chemotherapy and of those treated with pembrolizumab and platinum-based chemotherapy alone according to histology. |
up to 6 years
|
|
Progression Free Survival (PFS)
Tidsram: up to 6 years
|
PFS per RECIST v1.1 as assessed by BICR, in subjects treated with TTFields concomitant with pembrolizumab and platinum-based chemotherapy and of those treated with pembrolizumab and platinum-based chemotherapy alone according to PD-L1 Tumor Proportion Score (TPS). |
up to 6 years
|
|
Overall Survival (OS)
Tidsram: up to 6 years
|
OS in subjects treated with TTFields concomitant with pembrolizumab and platinum-based chemotherapy and of those treated with pembrolizumab and platinum-based chemotherapy alone according to PD-L1 TPS. |
up to 6 years
|
|
Progression Free Survival (PFS)
Tidsram: up to 6 years
|
PFS per RECIST v1.1 as assessed by BICR at 6 (PFS6), 12 (PFS12), 24 (PFS24), and 36 (PFS36) months in subjects treated with TTFields concomitant with pembrolizumab and platinum-based chemotherapy and of those treated with pembrolizumab and platinum-based chemotherapy alone. |
up to 6 years
|
|
1, 2, and 3-year Survival Rate
Tidsram: up to 6 years
|
1-, 2- and 3-year survival rate in subjects treated with TTFields concomitant with pembrolizumab and platinum-based chemotherapy and of those treated with pembrolizumab and platinum-based chemotherapy alone. |
up to 6 years
|
|
Objective Response Rate (ORR)
Tidsram: up to 6 years
|
Objective Response Rate (ORR) per RECIST v1.1 as assessed by BICR, in subjects treated with TTFields concomitant with pembrolizumab and platinum-based chemotherapy and of those treated with pembrolizumab and platinum-based chemotherapy alone. |
up to 6 years
|
|
Duration of Response (DoR)
Tidsram: up to 6 years
|
Duration of Response (DoR) per RECIST v1.1 as assessed by BICR, in subjects treated with TTFields concomitant with pembrolizumab and platinum-based chemotherapy and of those treated with pembrolizumab and platinum-based chemotherapy alone. |
up to 6 years
|
|
Disease Control Rate (DCR)
Tidsram: up to 6 years
|
Disease Control Rate (DCR) per RECIST v1.1 as assessed by BICR, in subjects treated with TTFields concomitant with pembrolizumab and platinum-based chemotherapy and of those treated with pembrolizumab and platinum-based chemotherapy alone. |
up to 6 years
|
|
Progression Free Survival (PFS)
Tidsram: up to 6 years
|
PFS per RECIST v1.1 as assessed by the investigator, in subjects treated with TTFields concomitant with pembrolizumab and platinum-based chemotherapy and of those treated with pembrolizumab and platinum-based chemotherapy alone. |
up to 6 years
|
|
Objective Response Rate (ORR)
Tidsram: up to 6 years
|
ORR per RECIST v1.1 as assessed by the investigator, in subjects treated with TTFields concomitant with pembrolizumab and platinum-based chemotherapy and of those treated with pembrolizumab and platinum-based chemotherapy alone. |
up to 6 years
|
|
Duration of Response (DoR)
Tidsram: up to 6 years
|
DoR per RECIST v1.1 as assessed by the investigator, in subjects treated with TTFields concomitant with pembrolizumab and platinum-based chemotherapy and of those treated with pembrolizumab and platinum-based chemotherapy alone. |
up to 6 years
|
|
Disease Control Rate (DCR)
Tidsram: up to 6 years
|
DCR per RECIST v1.1 as assessed by the investigator, in subjects treated with TTFields concomitant with pembrolizumab and platinum-based chemotherapy and of those treated with pembrolizumab and platinum-based chemotherapy alone. |
up to 6 years
|
|
Adverse Events
Tidsram: up to 6 years
|
Toxicity profile of TTFields concomitant with pembrolizumab and platinum-based chemotherapy. The analyses will be performed based on the incidence, severity, frequency of adverse events, and their association with study treatments. |
up to 6 years
|
Samarbetspartners och utredare
Sponsor
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
- Patologiska processer
- Neoplasmer efter plats
- Neoplasmer
- Luftvägssjukdomar
- Lungsjukdomar
- Neoplasmer i andningsvägarna
- Thoracic neoplasmer
- Neoplastiska processer
- Lungneoplasmer
- Karcinom, bronkogent
- Bronkiella neoplasmer
- Patologiska tillstånd, tecken och symtom
- Neoplasma Metastas
- Karcinom, icke-småcellig lunga
- Oorganiska kemikalier
- Platinaföreningar
- pembrolizumab
Andra studie-ID-nummer
- EF-44
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .